Form 4: Viridian COO Beetham Reports Equity Grants, Tax-Related Sales

Viridian Therapeutics' Chief Operating Officer, Thomas W. Beetham, reported significant equity grants of stock options and restricted stock units, alongside tax-related sales of common stock.

Summary

• Thomas W. Beetham, Chief Operating Officer of Viridian Therapeutics, Inc., reported several transactions involving the company's equity.
• On March 2, 2026, Mr. Beetham was granted 176,550 stock options with an exercise price of $30.25, which will vest in 48 equal monthly installments.
• Also on March 2, 2026, Mr. Beetham received a grant of 35,300 Restricted Stock Units (RSUs), which will vest 25% annually over four years.
• On March 3, 2026, 9,409 Restricted Stock Units (RSUs) from a grant dated March 3, 2025, vested and were converted into common stock.
• Concurrently on March 3, 2026, 3,138 shares of common stock were disposed of at a price of $29.32 per share, likely to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Mr. Beetham beneficially owns 13,271 shares of common stock, 176,550 stock options, and 28,227 Restricted Stock Units.
• The reported common stock ownership includes 1,000 shares acquired under the company's 2016 Employee Stock Purchase Plan (ESPP) on March 17, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive commitment through significant equity grants, which align management's interests with long-term shareholder value. The associated share disposition is a routine tax-related event.

Positives

• Chief Operating Officer Thomas W. Beetham received a substantial grant of 176,550 stock options, indicating continued incentive alignment with shareholder value.
• An additional grant of 35,300 Restricted Stock Units (RSUs) further aligns management's long-term interests with the company's performance.
• The vesting of 9,409 RSUs demonstrates the realization of previously granted equity compensation.

Negatives

• A disposition of 3,138 shares of common stock occurred at $29.32 per share, likely for tax withholding purposes, which reduces direct share ownership.

Future Outlook

The filing indicates a long-term commitment from the Chief Operating Officer through equity awards that vest over several years, specifically stock options vesting monthly over four years until March 2, 2030, and RSUs vesting annually over four years until March 2, 2030, and March 3, 2029, respectively.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Operating Officer are a standard practice in the biotechnology and pharmaceutical industry to incentivize long-term performance and retention. Such grants align executive interests with shareholder value creation, a common strategy among peers to foster innovation and achieve clinical milestones.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, including stock options with a 10-year term and RSUs vesting over four years, is consistent with typical executive compensation packages in the U.S. biotech sector.
• Companies like Moderna (MRNA) and BioNTech (BNTX) frequently utilize similar long-term incentive plans to retain top talent and drive strategic objectives, though the specific grant sizes vary based on company stage, executive role, and performance metrics.

Stakeholder Impact

• Shareholders: The grants align the COO's interests with long-term shareholder value creation, potentially fostering sustained performance. The tax-related sale is a minor, non-discretionary event.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• Stock options granted on March 2, 2026, will vest in 48 equal monthly installments, subject to continued service.
• Restricted Stock Units granted on March 2, 2026, will vest 25% on each yearly anniversary of the grant date over four years, subject to continued service.
• Remaining Restricted Stock Units from the March 3, 2025 grant will continue to vest annually over their four-year period.

Key Dates

Recommendation

The filing details routine executive compensation in the form of equity grants and a tax-related share disposition. While the grants demonstrate continued executive alignment, they do not present new fundamental information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational or financial updates.

Keywords

Viridian Therapeutics, VRDN, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Grant, Chief Operating Officer, Thomas W. Beetham, Executive Compensation